VendorMark said:Read four things before the headline number.
This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.
Dr.KarenChen said:My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.
A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced stroke risk (HR 0.82) over 3 years of follow-up[1].
These results complement the RCT data and suggest the benefits translate to real-world populations.
BethLabQueen said:I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.
BethLabQueen said:...regarding the trial evidence...
I think this is an underappreciated point. To expand on it with some data:
A recent meta-analysis of 22 RCTs (n=18,900) found that the trial evidence was associated with a consistent effect size across diverse patient populations[1].
The NNT was 20, which is comparable to metformin for T2DM prevention. That's a strong clinical argument for this approach.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after mike_mod’s answer:
How long did you give it before you decided it was working?
OP back with an update, since a thread like this is useless without one.
Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.